Common use of Tempus TIME TrialTM Program; Supported Collaborative Studies Clause in Contracts

Tempus TIME TrialTM Program; Supported Collaborative Studies. i) Tempus shall, upon GSK’s request at any time during the Term, provide GSK and its Affiliates with access to its Tempus Integrated Molecular Evaluation (TIME) TrialTM Program (the “Tempus TIME Program”) for any GSK Asset that is the subject of any GSK Research Program, including by facilitating collaboration with research sites and other partners within the Tempus TIME Program network, [***], facilitating rapid site activation, patient screening and initiation of clinical studies, and assisting with the design and implementation of clinical trials and research protocols. ii) If GSK and Tempus mutually agree to undertake an externally sponsored collaborative study with respect to one or more clinical development programs (“GSK-SCS”), with Tempus as the principal investigator, GSK and Tempus will enter into a separate Supported Collaborative Study Agreement with respect to any such study (a “GSK-SCS Agreement”), with any fees payable by GSK thereunder subject to the preferential pricing provisions set forth in Section 6.9. Any GSK-SCS Agreement shall provide that Tempus has the responsibility to contract with the relevant principal investigator and/or participating sites in connection therewith. iii) Any such participation in the Tempus TIME Program shall be subject to a Task Order or parallel GSK-SCS Agreement, as applicable, to be agreed among the Parties, which Task Order shall set forth, among other things, the fees and expenses for the applicable services to be performed within the Tempus TIME Program, [***]. iv) If Tempus expands the Tempus TIME Program to include additional territories or jurisdictions within the Tempus TIME Program network, GSK’s right to access the Tempus TIME Program shall extend to any such additional territories or jurisdictions.